➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

AstraZeneca
Baxter
McKinsey
Medtronic
Moodys
Johnson and Johnson

Last Updated: August 7, 2020

DrugPatentWatch Database Preview

FIRVANQ KIT Drug Profile

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Which patents cover Firvanq Kit, and what generic alternatives are available?

Firvanq Kit is a drug marketed by Rxmtm Theraps Llc and is included in one NDA. There is one patent protecting this drug.

This drug has seven patent family members in six countries.

The generic ingredient in FIRVANQ KIT is vancomycin hydrochloride. There are twenty-two drug master file entries for this compound. Twenty-four suppliers are listed for this compound. Additional details are available on the vancomycin hydrochloride profile page.

US ANDA Litigation and Generic Entry Outlook for Firvanq Kit

A generic version of FIRVANQ KIT was approved as vancomycin hydrochloride by FRESENIUS KABI USA on March 17th, 1987.

  Start Trial

Summary for FIRVANQ KIT
International Patents:7
US Patents:1
Applicants:1
NDAs:1
Suppliers / Packagers: 2
Formulation / Manufacturing:see details
DailyMed Link:FIRVANQ KIT at DailyMed
Drug patent expirations by year for FIRVANQ KIT
Paragraph IV (Patent) Challenges for FIRVANQ KIT
Tradename Dosage Ingredient NDA Submissiondate
FIRVANQ KIT FOR SOLUTION;ORAL vancomycin hydrochloride 208910 2020-05-18

US Patents and Regulatory Information for FIRVANQ KIT

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Rxmtm Theraps Llc FIRVANQ KIT vancomycin hydrochloride FOR SOLUTION;ORAL 208910-001 Jan 26, 2018 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
Rxmtm Theraps Llc FIRVANQ KIT vancomycin hydrochloride FOR SOLUTION;ORAL 208910-002 Jan 26, 2018 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Merck
Baxter
Express Scripts
Harvard Business School
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.